Condition
Hemicrania Continua
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 2 (1)
Trial Status
Terminated2
Enrolling By Invitation1
Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT06200480Not ApplicableTerminated
Nurse Intervention Trial
NCT02910323Recruiting
The Will Erwin Headache Research Center - Cluster Headache Study
NCT03511846Phase 1Enrolling By Invitation
Pain Biomarker Study
NCT04303845Phase 2TerminatedPrimary
Erenumab For Treatment of Hemicrania Continua
Showing all 4 trials